Akelos

About:

Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment.

Website: http://www.akelosinc.com/

Twitter/X: akelosi

Top Investors: National Institutes of Health

Description:

Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. It was founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. The company was founded in 2018 and is based in New York, NY, United States.

Total Funding Amount:

$2.05M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2018-01-01

Contact Email:

drstevefox(AT)akelosinc.com

Founders:

Steven R. Fox

Number of Employees:

11-50

Last Funding Date:

2020-01-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai